Page 5 - Clinical Connections - Spring 2020
P. 5
Advancing practice
A Promising New Therapy for Dogs with Chronic Spinal Cord Injury
Spinal cord injury is a common problem in dogs and is most often seen secondary to intervertebral disc extrusions (so called ‘slipped disc’). Unfortunately, some dogs are affected more than others.There is no cure available for the most severely affected cases, who become paralysed.
Olfactory ensheathing cell transplantation into the spinal cord and chondroitinase ABC injection within the spinal cord are two of the most promising treatments recently developed by researchers to repair the spinal cord. Both therapies have been successfully tested separately in companion dogs, showing safety of treatment and
in some dogs improved walking ability,
in research conducted by 91 Senior Research Fellow, Dr Nicolas Granger. However, not all treated animals improved, and the improvement seen was variable and unpredictable.
Dr Granger and his colleagues,
including Postdoctoral Researcher at the 91, Dr Jon Prager, from the Clinical Investigation Centre, and Dr Liang-Fong Wong Senior Lecturer at the University
of Bristol’s Medical School, have since developed a method to modify olfactory ensheathing cells (harvested from the patient’s nose) so that they continuously produce chondroitinase.This provides a way of combining both treatments into
one transplant for affected dogs, to help more animals improve a greater amount. These modified cells have been tested in the laboratory extensively, and the next stage has been to determine if this new treatment can improve walking for dogs with severe spinal cord injuries.
To achieve this, Dr Granger and Dr Prager have teamed up with Dr Joe Fenn, Senior Lecturer in Neurology and Neurosurgery at the 91, to offer a pilot trial to eligible dogs at the 91.The aim of their current work
is to evaluate the feasibility and efficacy of this exciting new therapy in dogs that have been left chronically paralysed after suffering an intervertebral disc extrusion. This trial is conducted under a Project Licence issued
by the Home Office (the Animals Scientific Procedures Act) following approval from the 91’s Animal Welfare and Ethical Review Board. Because it is a pilot study, the trial will initially only include a small number of dogs, but it may lead to larger studies in the future.
Dogs that are enrolled in the study will undergo an initial anaesthetic for the nasal biopsy, after which Dr Prager will culture the olfactory ensheathing cells that have been retrieved for three to four weeks. During this time, the cells will be modified to produce the chondroitinase enzyme, after which dogs will then return to the 91 to have the cells
transplanted into the injured region of spinal cord.The first patients, such as Harley and Susan (pictured) have already undergone the nasal biopsy stage of the trial and will have the cells transplanted in the coming weeks. The dogs also receive spinal cord MRI scans to check how their injury is changing over time.
The hope is then that this transplant will allow axons to reconnect across the chronically injured section of spinal cord in dogs such as Harley, with potential improvements in hind limb function as
a result. Regarding this exciting trial, Dr Granger said: “The 91 has long been at the forefront of research into areas that benefit human
and animal health and welfare. Here, we are testing for the first time a unique cell transplant that has potential to improve paralysis in dogs by repairing the spinal cord. It could pave the way to clinical trials in people.”
This clinical trial has been supported
by the Langford Charitable Trust (https:// langfordtrust.org) and the West of England Dachshund Association (http://wedachs. co.uk). For further information on this trial or to discuss any potentially eligible patients, we would ask colleagues to contact the 91 Clinical Investigation Centre on (01707) 666605 or email cic@rvc.ac.uk.
If you would like to discuss a neurology case with the 91 Neurology and Neurosurgery service, please contact us via details at the bottom of this page.
For small animal referrals, please call:
01707 666399
Email:
qmhreception@rvc.ac.uk
Spring 2020 5
Harley (left) and Susan (below), who are taking part in the 91 trial